mavyret.com — September 2026 traffic, keywords & AI visibility

Search engines send mavyret.com an estimated 6,461 visits a month. Effectively all of it is organic — about 6,442 visits from unpaid results. Paid search contributes only about 19 visits a month. Spread across 157 ranking keywords, that averages roughly 41 organic visits per keyword.

mavyret.com scores 67 out of 100 on our AI visibility scale, grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on mavyret.com runs to 73 lines (4,485 characters) across 12 sections, last generated in June 2026. It introduces the site as "Mavyret® (Glecaprevir and Pibrentasvir) Official Website". It tells AI engines the business works in Pharmaceuticals, Biotechnology and Infectious Disease Treatment. It describes 1 product, including Mavyret (Glecaprevir and Pibrentasvir). Services it lists include Patient Support Programs and Medical Information Services. The audience it names is Patients diagnosed with chronic Hepatitis C virus infection, aged Adults and children 3 years and older (Global (where approved)). Technologies it mentions include HTTPS, HTML5, CSS3 and JavaScript. The keywords it claims start with "Mavyret", "Hepatitis C treatment", "Hepatitis C cure" and "Mavyret dosage". It gives the company type as Pharmaceutical Brand.

# Mavyret® (Glecaprevir and Pibrentasvir) Official Website

## About
Mavyret stands as a leading prescription medication specifically designed for the treatment of chronic Hepatitis C virus (HCV) infection. Its primary appeal lies in its remarkably short treatment duration, offering a path to a cure for most eligible patients in just 8 weeks. This direct-acting antiviral therapy is broadly applicable across all six major HCV genotypes (GT1-6), making it a versatile option for a wide range of patients, including those with or without compensated cirrhosis, and individuals with specific kidney conditions.

The efficacy of Mavyret stems from its unique combination of two potent antiviral drugs: glecaprevir and pibrentasvir. These components work synergistically to directly target and inhibit the replication of the Hepatitis C virus at multiple stages of its life cycle, effectively clearing the virus from the body. Clinical trials have demonstrated high sustained virologic response (SVR) rates, meaning the virus remains undetectable 12 weeks after completing treatment, which is considered a definitive cure. Adherence to the prescribed regimen is crucial to achieving these optimal outcomes and ensuring the best possible chance of viral eradication.

While Mavyret offers a highly effective treatment, it is a prescription medicine and, like all medications, carries potential side effe

Google lists mavyret.com for about 157 keywords, which together bring an estimated 6,442 organic visits a month.

The latest technical audit of mavyret.com scored 0 out of 100 overall. The audit makes 12 recommendations in all, and 4 of the 4 listed first are rated high priority or critical.

Mavyret's company profile names Harvoni, Epclusa, Zepatier and Viekira Pak as competitors. Its own llms.txt adds https://www.drugs.com/harvoni.html and https://www.drugs.com/epclusa.html. Outside its market, the domains ranked closest to it in our worldwide ranking are hostingadam.com, dichuang.cc, smartwildagency.uk and houselaunchhaarlem.nl.

Harvoni

Epclusa

Zepatier

Viekira Pak

https://www.drugs.com/harvoni.html

https://www.drugs.com/epclusa.html